Skip to main content

Table 1 Baseline characteristics by treatment group

From: The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry

 

TNFi (N = 1806)a

IL-6Ri (N = 485)b

JAKi (N = 481)c

p value for crude group comparison

Age, years, mean (SD)

57.6 (12.9)

57.9 (13.1)

60.3 (12.1)

< 0.001

Duration of RA, years, mean (SD)

8.6 (8.9)

12.6 (9.4)

13.3 (10.0)

< 0.001d

Female, n (%)

1405 (77.8)

393 (81.0)

391 (81.3)

0.12

White race, n (%)

1492 (82.9)

401 (83.4)

410 (86.5)

0.17

No insurance, n (%)

24 (1.3)

N/A

5 (1.0)

0.48d

Current smoker, n (%)

332 (18.5)

75 (15.6)

88 (18.4)

 

BMI, mean (SD)

30.8 (7.6)

30.5 (7.4)

30.6 (7.1)

0.69

Seropositivity, n/N (%)e

    

 Anti-CCP antibody positive

480/1059 (45.3)

127/275 (46.2)

143/286 (50.0)

0.37

 RF positive

779/1204 (64.7)

187/306 (61.1)

198/307 (64.5)

0.50

Hb, g/dL, mean (SD)

13.46 (1.41)

13.58 (1.37)

13.19 (1.48)

 

Normal Hb, n (%)f

1505 (83.3)

392 (80.8)

391 (81.3)

 

Abnormal Hb, n (%)f

301 (16.7)

93 (19.2)

90 (18.7)

 

CRP, mg/dL, mean (SD)

0.89 (1.99)

0.63 (2.59)

1.01 (2.94)

 

Normal CRP, n (%)f

1112 (61.6)

279 (57.5)

317 (65.9)

 

Abnormal CRP, n (%)f

694 (38.4)

206 (42.5)

164 (34.1)

 

History of comorbidities, n (%)

    

 CVDg

192 (10.6)

58 (12.0)

60 (12.5)

0.44

 Malignancyh

111 (6.1)

37 (7.6)

37 (7.7)

0.31

 Serious infectionsi

143 (7.9)

43 (8.9)

50 (10.4)

0.21

CDAI, mean (SD)

17.7 (12.9)

20.1 (12.9)

18.3 (12.9)

< 0.001

CDAI category, n (%)

    

 Remission (< 2.8)

169 (9.4)

20 (4.2)

40 (8.3)

0.003

 Low (≥ 2.8 to < 10)

442 (24.6)

102 (21.2)

117 (24.3)

 

 Moderate (≥ 10 to < 22)

621 (34.5)

180 (37.4)

159 (33.1)

 

 High ( ≥ 22)

568 (31.6)

179 (37.2)

165 (34.3)

 

HAQ, mean (SD)

0.9 (0.7)

1.1 (0.7)

1.0 (0.7)

< 0.001

No prednisone use, n (%)

1272 (70.4)

313 (64.5)

347 (72.1)

0.10

Concomitant therapy as monotherapy, n (%)j

346 (19.2)

159 (32.8)

177 (36.8)

< 0.001

Biologic line of therapy, n (%)

    

 First

1388 (76.9)

295 (60.8)

313 (65.1)

< 0.001k

 Second

223 (12.3)

57 (11.8)

46 (9.6)

 

 Third or higher

195 (10.8)

133 (27.4)

122 (25.4)

 
  1. BMI body mass index, CCP cyclic citrullinated peptide, CDAI Clinical Disease Activity Index, CRP C-reactive protein, CVD cardiovascular disease, HAQ Health Assessment Questionnaire, Hb hemoglobin, IL-6Ri interleukin-6 receptor inhibitor, JAKi Janus kinase inhibitor, N/A not applicable, RA rheumatoid arthritis, RF rheumatoid factor, SD standard deviation, TNFi tumor necrosis factor inhibitor
  2. aCertolizumab pegol, n = 269; etanercept, n = 416; adalimumab, n = 522; infliximab, n = 280; golimumab, n = 319
  3. bTocilizumab, n = 433; sarilumab, n = 52
  4. cBaricitinib, n = 33; upadacitinib, n = 9; tofacitnib, n = 439
  5. dNon-parametric test was used: the Fisher exact test for categorical variables and Kruskal–Wallis test for continuous variables (for all other characteristics in the table, chi-square tests were used for categorical variables and one-way analysis of variance for continuous variables)
  6. eLaboratory monitoring is not mandated in this observational registry
  7. fNormal defined as Hb ≥ 12 g/dL for females and Hb ≥ 13 g/dL for males and CRP < 0.8 mg/dL
  8. gHistory of CVD includes myocardial infarction, stroke, acute coronary syndrome, coronary artery disease, coronary heart failure, revascularization procedure including percutaneous coronary intervention, coronary artery bypass grafting or coronary artery stents, ventricular arrhythmia, cardiac arrest, unstable angina, peripheral arterial disease, other cardiovascular events, pulmonary embolism, carotid artery disease, deep vein thrombosis, and transient ischemic attack
  9. hHistory of malignancy includes lymphoma, lung cancer, breast cancer, non-melanoma skin cancer, and other cancers
  10. iSerious infections include infections that led to hospitalization or intravenous antibiotics: joint/bursa, cellulitis, sinusitis, diverticulitis, sepsis, pneumonia, bronchitis, gastroenteritis, meningitis, urinary tract infection, upper respiratory tract infection, or infection of other specified sites
  11. jConcomitant therapy excludes any disease-modifying anti-rheumatic drug
  12. kIn addition, there was a statistically significant difference (p < 0.001) for the IL-6Ri and JAKi groups combined, compared with the TNFi group
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us